medigraphic.com
SPANISH

Ginecología y Obstetricia de México

Federación Mexicana de Ginecología y Obstetricia, A.C.
  • Contents
  • View Archive
  • Information
    • General Information        
    • Directory
  • Publish
    • Instructions for authors        
  • medigraphic.com
    • Home
    • Journals index            
    • Register / Login
  • Mi perfil

2011, Number 07

<< Back Next >>

Ginecol Obstet Mex 2011; 79 (07)

Carbetocin Use to prevent obstetric hemorrhage

Posadas RFJ
Full text How to cite this article

Language: Spanish
References: 12
Page: 419-427
PDF size: 477.85 Kb.


Key words:

obstetric haemorrhage, carbetocin, oxytocin, caesarean section.

ABSTRACT

Background: in Mexico, obstetric hemorrhage and its complications are the second leading cause of maternal death and is the origin of irreversible functional consequences. Carbetocin is a synthetic analogue of oxytocin with an average lifespan four times that of oxytocin and pharmacological effects of 120 minutes produces a tonic contraction which reduces postpartum blood loss.
Objective: To evaluate the usefulness of carbetocin to prevent uterine bleeding complications and maternal deaths and assess the benefits, effectiveness and side effects.
Patients and methods: Prospective, observational clinical research in two phases, the first from May 2005 to January 2006 with a sample of 40 patients and the second from January to December of 2008 with a sample of 72 patients conducted at the Hospital Materno Infantil Dr. Alberto López Hermosa, San Luis Potosi. All were high-risk pregnancies and medical complications that warranted specialty hospital management. The intervention consisted of applying undiluted single dose of 100 micrograms of intravenous carbetocin at the time of delivery, as prophylaxis in patients with uterine overdistention in the first phase of the study and complicated pregnancies in the second phase.
Results: were born by caesarean section over 60%. Initially, the hemoglobin showed a reduction of 17% after delivery. Seven patients required blood transfusion (17.5%). In the second phase, 65 patients (90%) did not require transfusion, only 6 patients (8%) required transfusion. No side effects were documented. Uterine overdistension was the main risk factor for bleeding and transfusion.
Conclusions: carbetocin combines the safety of oxytocin and the strength of the ergonovine preparations. To determine where carbetocin will be situated in the future as an useful oxytocic, it requires more than a simple demonstration of its effectiveness. This should be determined in each clinical situation, with factors such as overdistended uterus, indicating the convenience and economic constraints.


REFERENCES

  1. Organización Panamericana de la Salud. Contra la mortalidad materna. Boletín Informativo febrero 2010.

  2. Secretaría de Salud. Lineamiento Técnico: Prevención, Diagnóstico y Manejo de la Hemorragia Obstétrica. Centro Nacional de Equidad de Género y Salud Reproductiva. México, 2009.

  3. El Colegio de México. Las mujeres en la pobreza. Centro de Estudios Sociológicos, Grupo Interdisciplinario sobre Mujer, Trabajo y Pobreza. México, 1997;221-226

  4. Dansereau J, Joshi, AK, Michael E. Comparative study double blind between the carbetocin and the oxytocin in the prevention of the uterine atony after a Caesarean operation. Am J Obstet Gynecol 1999;180:670-676.

  5. Karchmer S, Fernández del Castillo C. Obstetricia y Medicina Perinatal. México:COMEGO, 2000; Tomo I: Capítulo IV. Complicaciones del parto y puerperio;479-510.

  6. Secretaría de Salud. Lineamiento Técnico: Prevención, diagnóstico y manejo de la hemorragia obstétrica: Dirección General de Salud Reproductiva. México, 2002.

  7. Angulo VJ, Cortés SL, Torres GLG, Aguayo AG, Hernández HS, Avalos NJ. Análisis de la mortalidad materna en tres periodos en el Hospital de Ginecología y Obstetricia del Centro Médico Nacional de Occidente. Ginec y Obst Mex 2007;75:384-392

  8. Angulo RE, Andueza PG, Montero CL. Subregistro de Muertes Maternas en Yucatán. Ginec y Obstet Mex 2005;73:347-354.

  9. Elboume DR. Active vs conservative third stage management: pregnancy and childbirth module. En: Enkin MW, Keirse MJNC. Renfrew MJ. Neilson JP, editors. Cochrane database of systematic reviews. Oxford: Software de actualización; 1994. Edición No. 1. Revisión No. 05352.

  10. Boucher M, Nimrod CA, Tawagi GF, Meeker TA, et al. Comparison of carbetocin and oxytocin for the prevention of postpartum hemorrhage following vaginal delivery: a double-blind randomized trial. J Obstet Gynaecol Can 2004;26(5):481-488.

  11. Soto GC, Germes PF, García JG. Utilidad de la fórmula Jhonson y Toshach para calcular el peso fetal en embarazos de término en un hospital de segundo nivel. Ginecol Obstet Méx 2007;75;317-324.

  12. López Llera M. La toxemia del embarazo. Lecciones básicas; Papel de la viscosidad sanguínea en la microcirculación intervellosa. México: Editorial Limusa, 1985;113.




2020     |     www.medigraphic.com

Mi perfil

C?MO CITAR (Vancouver)

Ginecol Obstet Mex. 2011;79